Open AccessDetection of Bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in Urine and Blood Specimens after Intravesical Immunotherapy for Bladder Carcinoma
Author(s) -
Argyris Siatelis,
Dimitra Houhoula,
Joseph Papaparaskevas,
Dimitrios Delakas,
Athanassios Tsakris
Publication year - 2011
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01595-10
Subject(s) - mycobacterium bovis , immunotherapy , medicine , bcg vaccine , urine , carcinoma , mycobacterium tuberculosis , tuberculosis , malignancy , mycobacterium tuberculosis complex , pathology , microbiology and biotechnology , biology , immunology , immune system
A real-time PCR targeting IS6110 was employed for the detection ofMycobacterium tuberculosis DNA in specimens collected from 10 patients treated with intravesicalM. bovis bacillus Galmette-Guérin (BCG) immunotherapy for bladder malignancy. BCG DNA was detected in all urine specimens taken 24 h after the instillations, as well as in 24% of the specimens collected 7 days after the instillations; it was also detected in a single specimen taken 6 weeks after the last instillation. BCG DNA was detected in 8.3% of the blood specimens taken 1 day after instillation, and its amplification was associated with cases of self-limiting fever. These findings give indications that this real-time PCR is helpful to recognize BCG bacteremic cases, which may lead to mycobacterial infection.